Skip to main content
TipRanks
Go Ultimate75% OFF

Compare GlaxoSmithKline (GS71) vs. Competitors

0 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
CH:GS71GlaxoSmithKlineCHF 26.12CHF 85.69B17.860.00%HoldUnlock the CH:GS71 analyst price target with TipRanks PremiumCH:GS71Unlock the CH:GS71 top-analyst price target with TipRanks Premium
GB:AZNAstraZenecaGBX 13,802.00GBX 217.66B25.991.55%Strong BuyUnlock the GB:AZN analyst price target with TipRanks PremiumCH:GS71 vs GB:AZNUnlock the GB:AZN top-analyst price target with TipRanks Premium
GB:HIKHikma PharmaceuticalsGBX 1,675.00GBX 3.47B12.356.21%Strong BuyUnlock the GB:HIK analyst price target with TipRanks PremiumCH:GS71 vs GB:HIKUnlock the GB:HIK top-analyst price target with TipRanks Premium
GB:SNSmith & NephewGBX 1,152.00GBX 9.83B20.40-7.47%HoldUnlock the GB:SN analyst price target with TipRanks PremiumCH:GS71 vs GB:SNUnlock the GB:SN top-analyst price target with TipRanks Premium
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegSGBX 57.50GBX 67.05B4.6641.98%―Unlock the GB:BXP analyst price target with TipRanks PremiumCH:GS71 vs GB:BXPUnlock the GB:BXP top-analyst price target with TipRanks Premium
GB:HLNHaleon PLCGBX 342.30GBX 30.40B19.11-7.36%Moderate BuyUnlock the GB:HLN analyst price target with TipRanks PremiumCH:GS71 vs GB:HLNUnlock the GB:HLN top-analyst price target with TipRanks Premium

Performance Comparison

-40%-20%0%20%40%60%80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
CH:GS71GlaxoSmithKline26.110.000.00%
GB:AZNAstraZeneca13802.00463.913.48%
GB:HIKHikma Pharmaceuticals1675.00186.4312.52%
GB:SNSmith & Nephew1152.00-54.01-4.48%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS57.5018.8048.60%
GB:HLNHaleon PLC342.30-16.92-4.71%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts